Cannabidiol and Fragile X syndrome | webinar with Dr Heussler, July 2023

Presentation from “Fragile X Syndrome Research Roundup” webinar 1 of 2, 13 July 2023.
Assoc Prof Helen (Honey) Heussler provided an overview of the scientific rationale that underpins the current RECONNECT cannabidiol (CBD) clinical trial in Fragile X syndrome. Dr Heussler outlined the working of the human endocannabinoid system, the impact of Fragile X syndrome on that system, and how cannabidiol (non-THC CBD) can provide regulation and control. Dr Heussler outlined the operation and findings of the clinical trial phases which preceded the current Zynerba RECONNECT study.
The RECONNECT study is open at 4 sites in Australia, and is seeking to involve participants aged 3-17 / 3-22 years of age who have a diagnosis of Fragile X syndrome. The study is looking to understand whether the ZYGEL CBD transdermal gel product helps in some behavioural issues associated with Fragile X syndrome. fragilexhelp.com.au/
Webinar AV hosting and video production by AlbaPrime. www.albaprime.com/

[@scottfree6869]

Thanks - great, factual, detailed presentation.